Adamas Releases Final Results of Two-Year Phase 3 Trial of GOCOVRI® for Dyskinesia
(February 11, 2020) The longest-running amantadine study to date of the only FDA-approved medicine for dyskinesia indicates GOCOVRI may help people with PD who are struggling to manage levodopa-related motor complications. Read more.
Save the Date for the 26th Parkinson’s Unity Walk on April 25, 2020, in Central Park, New York City
February 3, 2020 — Last year the Parkinson’s Unity Walk raised over $1.5 million dollars to support research to end Parkinson’s disease. This epic event brings the leading Parkinson’s organizations, medical doctors, therapists, pharmaceutical, and sup …
Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film
January 2, 2020— Sunovion Pharmaceuticals, Inc. issued a press release announcing that its New Drug Application (NDA) for apomorphine sublingual film (APL-130277) has been accepted by the U.S. Food and Drug Administration. This on-demand treatment is b …